← Back to Search

Other

Continuous Wound Infusion for Total Knee Replacement

N/A
Waitlist Available
Led By Gordon Arnett, MD
Research Sponsored by Capital Health, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ASA risk classification of 1 or 2
Do not regularly use opioid medication pre-operatively
Must not have
Deemed unfit for continuous wound infusion due to allergies
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial will compare pain and other patient outcomes after total knee replacement when using a continuous wound analgesia system, versus usual methods of pain control.

Who is the study for?
This trial is for adults under 70 in Edmonton needing a knee replacement, who can understand English and have someone to care for them at home. They should be healthy enough for surgery with no allergies to Bupivacaine, not use opioids regularly, have a BMI under 40, and must provide consent.
What is being tested?
The study compares the effectiveness of continuous wound infusion pain relief using On-Q PainBuster with Bupivacaine against usual pain control methods after knee replacement surgery. It also assesses if this method eases nursing care.
What are the potential side effects?
Possible side effects may include reactions to Bupivacaine such as numbness around the wound area, weakness, nausea or vomiting. There might also be risks associated with the device like infection or discomfort at the infusion site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My health is good or fairly good.
Select...
I do not regularly take opioid painkillers before surgery.
Select...
I can bend my knee more than 90 degrees.
Select...
My liver functions normally.
Select...
I am scheduled for a knee replacement at the Royal Alexandra Hospital.
Select...
I understand the study and agree to participate.
Select...
I am planning to have surgery that is not due to an injury.
Select...
I am younger than 70 years old.
Select...
I will receive spinal anesthesia during surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am allergic to materials used in continuous wound infusions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SExperimental Treatment1 Intervention
Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
Group II: CActive Control1 Intervention
Usual care - post operative pain medications as per the knee arthroplasty care map.

Find a Location

Who is running the clinical trial?

Capital Health, CanadaLead Sponsor
15 Previous Clinical Trials
20,035 Total Patients Enrolled
Gordon Arnett, MDPrincipal InvestigatorCapital Health, Canada

Media Library

On-Q PainBuster with Bupivacaine (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00724074 — N/A
Total Knee Replacement Research Study Groups: S, C
Total Knee Replacement Clinical Trial 2023: On-Q PainBuster with Bupivacaine Highlights & Side Effects. Trial Name: NCT00724074 — N/A
On-Q PainBuster with Bupivacaine (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00724074 — N/A
~13 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top